UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib: Preclinical Study

Hypertension (Dallas, Tex. 1979), 2014-12, Vol.64 (6), p.1282-1289

2014

Volltextzugriff (PDF)

A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients

British journal of clinical pharmacology, 2017-02, Vol.83 (2), p.294-313

2017

Volltextzugriff (PDF)

Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression

The journal of clinical endocrinology and metabolism, 2011-10, Vol.96 (10), p.3087-3094

2011

Volltextzugriff (PDF)

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

Journal of clinical oncology, 2009-09, Vol.27 (26), p.4406-4412

2009

Volltextzugriff (PDF)

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4707-4713

2007

Volltextzugriff (PDF)

Effects of St. John's Wort on Irinotecan Metabolism

JNCI : Journal of the National Cancer Institute, 2002-08, Vol.94 (16), p.1247-1249

2002

Volltextzugriff (PDF)

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR‐145 and miR‐451 as tumor suppressors

International journal of cancer, 2014-07, Vol.135 (2), p.348-361

2014

Volltextzugriff (PDF)

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

The pharmacogenomics journal, 2019-10, Vol.19 (5), p.473-479

2019

Volltextzugriff (PDF)

Incident cancer risk after the start of aspirin use: Results from a Dutch population‐based cohort study of low dose aspirin users

International journal of cancer, 2014-07, Vol.135 (1), p.157-165

2014

Volltextzugriff (PDF)

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3240-3246

2011

Volltextzugriff (PDF)

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer

Molecular oncology, 2023-09, Vol.17 (9), p.1898-1907

2023

Volltextzugriff (PDF)

Can erlotinib ameliorate cisplatin-induced toxicities?

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3442-3443

2013

Volltextzugriff (PDF)

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (21), p.1585-1592

2004

Volltextzugriff (PDF)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Molecular oncology, 2019-08, Vol.13 (8), p.1795-1807

2019

Volltextzugriff (PDF)

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

Circulation research, 2021-04, Vol.128 (7), p.1040-1061

2021

Volltextzugriff (PDF)

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.612-623

2024

Volltextzugriff (PDF)

Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.1006-1016

2024

Volltextzugriff (PDF)

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation

Hepatology communications, 2022-09, Vol.6 (9), p.2565-2568

2022

Volltextzugriff (PDF)

Integrated semi‐physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.809-819

2015

Volltextzugriff (PDF)

DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity

Molecular oncology, 2014-05, Vol.8 (3), p.458-468

2014

Volltextzugriff (PDF)

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1309-1314

2016

Volltextzugriff (PDF)

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis

Journal of clinical oncology, 2023-12, Vol.41 (35), p.5411-5421

2023

Volltextzugriff (PDF)

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.995-1006

2024

Volltextzugriff (PDF)

Darolutamide does not interfere with OATP‐mediated uptake of docetaxel

International journal of cancer, 2024-07, Vol.155 (2), p.314-323

2024

Volltextzugriff (PDF)

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Value in health, 2024-10, Vol.27 (10), p.1367-1372

2024

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Humans
(45)
Oncology
(29)
Male
(28)
Female
(25)
Aged
(21)
Middle Aged
(21)
Adult
(19)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Tumors
(14)
Camptothecin - Analogs & Derivatives
(11)
Camptothecin - Pharmacokinetics
(10)
Cancer
(10)
Pharmacology & Pharmacy
(10)
Chemotherapy
(9)
Pharmacokinetics
(9)
Prospective Studies
(9)
Antineoplastic Agents, Phytogenic - Pharmacokinetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib: Preclinical Study

A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients

Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Effects of St. John's Wort on Irinotecan Metabolism

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR‐145 and miR‐451 as tumor suppressors

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

Incident cancer risk after the start of aspirin use: Results from a Dutch population‐based cohort study of low dose aspirin users

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer

Can erlotinib ameliorate cisplatin-induced toxicities?

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib

Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation

Integrated semi‐physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib

Darolutamide does not interfere with OATP‐mediated uptake of docetaxel

Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands

Aktive Filter

Suchergebnisse filtern